Ferreira, Rui Seabra [UNESP]de Barros, Luciana Curtolo [UNESP]Abbade, Luciana Patrícia Fernandes [UNESP]Barraviera, Silvia Regina Catharino Sartori [UNESP]Silvares, Maria Regina Cavariani [UNESP]de Pontes, Leticia Gomes [UNESP]dos Santos, Lucilene Delazari [UNESP]Barraviera, Benedito [UNESP]2018-12-112018-12-112017-04-04Journal of Venomous Animals and Toxins Including Tropical Diseases, v. 23, n. 1, 2017.1678-91991678-9180http://hdl.handle.net/11449/174422Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.engBuffaloesCryoprecipitate coagulumFibrin sealantSnake venomThrombin-like enzymeResenha10.1186/s40409-017-0109-8S1678-91992017000100204Acesso aberto2-s2.0-85016943744S1678-91992017000100204.pdf80849745430295159348918548022920